ANBIO BIOTECHNOLOGY LTD
NNNNNASDAQTrading Snapshot
- Day Range
- $9.81 – $9.95
- 52-Week Range
- $8.30 – $54.95
- Volume
- $3.44B
- Avg Volume
- $3.10B
- Shares Outstanding
- 43.9M
- Next Earnings
- Sep 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $9M
- Last Q Revenue
- $5M
- P/E Ratio
- 143.7
- P/S Ratio
- 110.8x
- EPS (TTM)
- $0.23
- Dividend Yield
- —
Why Investors Own NNNN
- ✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ANBIO BIOTECHNOLOGY LTD
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
